NO305705B1 - Fremgangsmate for fremstilling av et gjaerglukan - Google Patents

Fremgangsmate for fremstilling av et gjaerglukan Download PDF

Info

Publication number
NO305705B1
NO305705B1 NO19912645A NO912645A NO305705B1 NO 305705 B1 NO305705 B1 NO 305705B1 NO 19912645 A NO19912645 A NO 19912645A NO 912645 A NO912645 A NO 912645A NO 305705 B1 NO305705 B1 NO 305705B1
Authority
NO
Norway
Prior art keywords
glucan
insoluble
yeast residue
residue
insoluble yeast
Prior art date
Application number
NO19912645A
Other languages
English (en)
Norwegian (no)
Other versions
NO912645D0 (no
NO912645L (no
Inventor
Gunnar Rorstad
Borre Robertson
Jan Raa
Original Assignee
Biotec Mackzymal Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotec Mackzymal Asa filed Critical Biotec Mackzymal Asa
Publication of NO912645D0 publication Critical patent/NO912645D0/no
Publication of NO912645L publication Critical patent/NO912645L/no
Publication of NO305705B1 publication Critical patent/NO305705B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/064Saccharomycetales, e.g. baker's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Catching Or Destruction (AREA)
NO19912645A 1990-07-06 1991-07-05 Fremgangsmate for fremstilling av et gjaerglukan NO305705B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54957590A 1990-07-06 1990-07-06

Publications (3)

Publication Number Publication Date
NO912645D0 NO912645D0 (no) 1991-07-05
NO912645L NO912645L (no) 1992-01-07
NO305705B1 true NO305705B1 (no) 1999-07-12

Family

ID=24193557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19912645A NO305705B1 (no) 1990-07-06 1991-07-05 Fremgangsmate for fremstilling av et gjaerglukan

Country Status (12)

Country Link
US (1) US5401727A (de)
EP (1) EP0466037B1 (de)
JP (1) JP2828799B2 (de)
AT (1) ATE160787T1 (de)
AU (1) AU628752B2 (de)
CA (1) CA2040374C (de)
DE (1) DE69128308T2 (de)
DK (1) DK0466037T3 (de)
ES (1) ES2109929T3 (de)
FI (1) FI104537B (de)
GR (1) GR3026130T3 (de)
NO (1) NO305705B1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0665649B2 (ja) * 1991-02-01 1994-08-24 台糖株式会社 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
PT664671E (pt) * 1993-08-06 2003-01-31 Biotec Pharmacon Asa Racoes para animais compreendendo glucano de levedura
JPH08113539A (ja) * 1993-09-22 1996-05-07 Nippon Paper Ind Co Ltd 免疫増強剤及びその製造方法、並びにそれを用いた甲殻類及び魚類の養殖用飼料
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5871751A (en) * 1994-10-12 1999-02-16 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Renibacterium salmoninarum vaccine and method for its preparation
JP3744020B2 (ja) * 1995-04-14 2006-02-08 日本製紙株式会社 免疫増強剤並びにそれを含有する甲殻類、魚類及び家畜用飼料
CA2231244C (en) 1995-09-05 2009-04-14 Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh Anti-stress agents for aquatic animals
US5722346A (en) * 1996-04-17 1998-03-03 The Board Of Governors For Higher Education Smolting feed
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
AU6691598A (en) * 1997-04-18 1998-11-13 Immudyne, Inc. Gel delivery system for animal nutrition and health
CA2344166C (en) * 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
US7030101B2 (en) 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US20040127458A1 (en) * 2000-11-06 2004-07-01 Hunter Kenneth W. Beta-glucan containing compositions, methods for manufacturing beta-glucans, and for manufacturing and using beta-glucans and conjugates thereof as vaccine adjuvants
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US7323140B2 (en) * 2001-03-28 2008-01-29 Handylab, Inc. Moving microdroplets in a microfluidic device
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
KR20050043751A (ko) * 2001-11-06 2005-05-11 오리엔트 캔서 세라피 컴퍼니 리미티드 항암 조성물
DE10222358A1 (de) * 2002-05-21 2003-12-11 Nutrinova Gmbh ß-Glucanhaltiges Sorbinsäurepräparat als Futtermittelzusatz in der Nutztieraufzucht
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
GB0225503D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Gel feed
GB0225502D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Therapeutic and prophylactic preparations
JP2004210895A (ja) * 2002-12-27 2004-07-29 Immudyne Japan:Kk 免疫機能を有する可能性β−グルカンの製造方法及び用途
JP2007524354A (ja) * 2003-01-29 2007-08-30 イミュダイン インコーポレーティッド 動物用の免疫増強剤
GB2399752A (en) * 2003-03-26 2004-09-29 Micap Plc Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant
PL1711058T3 (pl) 2004-01-23 2022-02-07 Eden Research Plc Sposoby zabijania nicieni obejmujące aplikację składnika terpenowego
DK1753529T3 (da) 2004-05-20 2013-11-11 Eden Research Plc Komposition indeholdende en hul glucan-partikel eller en hul cellevægspartikel, der indkapsler en terpenkomponent, fremgangsmåder til fremstilling og anvendelse af disse
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101052383B (zh) * 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
US7306818B2 (en) * 2005-01-03 2007-12-11 Promd Biotech Co., Ltd. Method for preventing and/or treating viral infection in aquatic animals
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
JP5489462B2 (ja) * 2005-10-24 2014-05-14 ユニバーシティ オブ マサチューセッツ 骨病状の遺伝子治療のための組成物およびそれらの使用法
EP2982244B1 (de) 2005-11-30 2020-11-18 Eden Research Plc Thymolhaltige Insektizide Kapseln und Verfahren zu ihrer Herstellung und Verwendung
EP1954130B1 (de) 2005-11-30 2018-06-13 Eden Research Plc Verfahren umfassend terpenmischungen enthaltend thymol und citral
WO2008102151A1 (en) * 2007-02-21 2008-08-28 Biotec Pharmacon Asa Medical uses of glucans
JP5153188B2 (ja) * 2007-03-30 2013-02-27 小林製薬株式会社 Th1/Th2バランス改善剤
US20090061049A1 (en) * 2007-08-28 2009-03-05 Vadood Azarm Feed compositions for aquatic animals and methods of making the same
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
CA2705642A1 (en) * 2007-11-13 2009-05-22 Biotec Pharmacon Asa Methods of treating or preventing inflammatory diseases of the intestinal tract
CA2705544A1 (en) * 2007-11-19 2009-05-28 Calanus As Bioactive copepod-compositions, processes for the production thereof, and use thereof to prevent or treat hosts infested by phylogenetically similar ectoparasites
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US20100267661A1 (en) * 2009-03-17 2010-10-21 Immudyne, Inc. Beta glucans and methods of use thereof
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 rna 간섭
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
WO2012120290A2 (en) 2011-03-04 2012-09-13 Sana Pharma As Cosmetic formulations
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
US20160278367A1 (en) 2013-11-21 2016-09-29 Eden Research Plc Pesticidal Composition
CN105960265A (zh) 2013-12-04 2016-09-21 阿克赛医药公司 利用经化学修饰的寡核苷酸处理伤口愈合的方法
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3234141A4 (de) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir-tm-verbindungen
GB201501793D0 (en) 2015-02-03 2015-03-18 Eden Research Plc Encapsulation of high potency active agents
KR20180026739A (ko) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
EP3138573A1 (de) * 2015-07-09 2017-03-08 Danstar Ferment AG Zusammensetzungen und verfahren zur stimulation der immunantwort in menschen und/oder tieren
JP2018531037A (ja) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション 長い非コードrnaを標的とする減少したサイズの自己送達型核酸化合物
CN106719136A (zh) * 2016-11-30 2017-05-31 蚌埠市渔歌农业科技有限公司 一种防治鲶鱼病害的养殖方法
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
JP6530846B1 (ja) * 2018-10-09 2019-06-12 アサヒグループホールディングス株式会社 免疫賦活剤及び感染予防方法
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
JPWO2022244580A1 (de) * 2021-05-21 2022-11-24
TW202449152A (zh) 2023-02-09 2024-12-16 美商艾拉倫製藥股份有限公司 Reversir分子及其使用方法
WO2025078537A1 (en) 2023-10-10 2025-04-17 Ab Mauri (Uk) Ltd Compositions comprising branched (1,3)(1,6)-beta-glucans for use in the treatment of cancer
WO2025078523A1 (en) 2023-10-10 2025-04-17 Ab Mauri (Uk) Ltd Compositions comprising a combination of (1,3)(1,6)-beta-glucans and uses thereof in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301848A (en) * 1962-10-30 1967-01-31 Pillsbury Co Polysaccharides and methods for production thereof
GB2076418A (en) * 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
JPS6120561A (ja) * 1984-07-09 1986-01-29 住友ベークライト株式会社 医療用吸着剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
JPS6337801A (ja) * 1986-07-31 1988-02-18 Matsushita Electric Ind Co Ltd タ−ンテ−ブル
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine

Also Published As

Publication number Publication date
ES2109929T3 (es) 1998-02-01
CA2040374A1 (en) 1992-01-07
DE69128308D1 (de) 1998-01-15
JPH04253703A (ja) 1992-09-09
FI913275L (fi) 1992-01-07
US5401727A (en) 1995-03-28
DE69128308T2 (de) 1998-03-26
FI913275A0 (fi) 1991-07-05
EP0466037B1 (de) 1997-12-03
FI104537B (fi) 2000-02-29
EP0466037A2 (de) 1992-01-15
NO912645D0 (no) 1991-07-05
EP0466037A3 (en) 1992-10-28
JP2828799B2 (ja) 1998-11-25
AU628752B2 (en) 1992-09-17
NO912645L (no) 1992-01-07
CA2040374C (en) 1998-06-16
GR3026130T3 (en) 1998-05-29
DK0466037T3 (da) 1998-08-10
AU7933891A (en) 1992-01-23
ATE160787T1 (de) 1997-12-15

Similar Documents

Publication Publication Date Title
NO305705B1 (no) Fremgangsmate for fremstilling av et gjaerglukan
Chang et al. Effect of dietary β-1, 3-glucan on resistance to white spot syndrome virus (WSSV) in postlarval and juvenile Penaeus monodon
Robertsen et al. Enhancement of non‐specific disease resistance in Atlantic salmon, Salmo salar L., by a glucan from Saccharomyces cerevisiae cell walls
Ogier de Baulny et al. Effect of long-term oral administration of beta-glucan as an immunostimulant or an adjuvant on some non-specific parameters of the immune response of turbot Scophthalmus maximus
Rojo-Cebreros et al. Immunostimulation and trained immunity in marine fish larvae
Egidius et al. Bath‐immunization—a practical and non‐stressing method of vaccinating sea farmed rainbow trout Salmo gairdneri Richardson against vibriosis
EP0384323B1 (de) Zusammensetzung und Verfahren zur Erhöhung der Wirkung eines Fischvakzins
WO2015074946A1 (en) Fish vaccine
CN101461940B (zh) 美人鱼发光杆菌疫苗及其制备方法和应用
JPH062676B2 (ja) 水溶性グルカンからなる魚病の予防剤
EP3071227B1 (de) Fischimpfstoff
McCarthy An experimental model for fish furunculosis caused by Aeromonas salmonicida
Dalmo et al. Prophylactic effect of β (1, 3)‐D‐glucan (laminaran) against experimental Aeromonas salmonicida and Vibrio salmonicida infections
WO2009080767A1 (en) Fish vaccine
JPH0665649B2 (ja) 甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
WO2008074783A1 (en) Immune stimulant against fish pathogenic bacteria
JP3151068B2 (ja) 真珠貝への真珠核挿入方法
Zhu et al. The effect of dietary chitosan and chitin supplementation on the survival and immune reactivity of crayfish, Procambarus clarkii
Munn Vibriosis in fish and its control
Harrell Immunization of fishes in world mariculture: a review
JPH07108859B2 (ja) 魚類の感染症予防用薬剤
JPH08113539A (ja) 免疫増強剤及びその製造方法、並びにそれを用いた甲殻類及び魚類の養殖用飼料
Nagabhushanam Subunit Vaccines
Pedersen et al. IN MODERNEEL (ANGUILLA ANGUILLA) FARMING?
CN1176139A (zh) 鸡马立克氏病疫苗免疫增强剂及制备工艺

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS POSTBOKS 6963 ST OLAVS PLASS OSLO, 013

MK1K Patent expired